Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia

Neuropsychopharmacology

Volumn 30, Issue 12, 2005, Pages 2275-2282

  Holcomb, Henry H ^a,d   Lahti, Adrienne C ^a   Medoff, Deborah R ^a   Cullen, Tom ^b   Tamminga, Carol A ^c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Anterior cingulate; Ketamine; NMDA; PET; Schizophrenia

Indexed keywords

GLUTAMIC ACID; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; BLOOD FLOW; BRAIN BLOOD FLOW; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FRONTAL CORTEX; HUMAN; HYPERMETABOLISM; MALE; NEUROTRANSMISSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA;

ADULT; CEREBRAL CORTEX; CEREBROVASCULAR CIRCULATION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GYRUS CINGULI; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; KETAMINE; MALE; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 27844508674     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300824     Document Type: Article

References (58)

1. Adams BW, Moghaddam B (2001). Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol Psychiatry 50: 750-757.
2. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A et al (2000). Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gene Psychiatry 57: 270-276.
3. Arvanov VL, Wang RY (1999). Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine. J Pharmacol Exp Ther 289: 1000-1006.
4. Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L et al (1997). Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gene Psychiatry 54: 959-965.
5. Behar KL, Rothman DL (2001). In vivo nuclear magnetic resonance studies of glutamate-gamma-aminobutyric acid-glutamine cycling in rodent and human cortex: the central role of glutamine. J Nutr 131: 2498S-2504S.
6. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D (1997). Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 154: 805-811.
7. Cannon-Spoor HE, Potkin SG, Wyatt RJ (1982). Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull 8: 470-484.
8. Carpenter Jr WT (1999). The schizophrenia ketamine challenge study debate. Biol Psychiatry 46: 1081-1091.
9. Carter K, Dickerson J, Schoepp DD, Reilly M, Herring N, Williams J et al (2004). The mGlu2/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK-801: possible implications for psychosis. Neuropharmacology 47: 1135-1145.
10. Duncan GE, Leipzig JN, Mailman RB, Lieberman JA (1998). Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 812: 65-75.
11. Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA (1999). Comparison of brain metabolic activity patterns induced by ketamine, MK- 801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res 843: 171-183.
12. Duncan GE, Miyamoto S, Lieberman JA (2003). Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation. J Pharmacol Exp Ther 305: 999-1005.
13. Farber NB (2003). The NMDA receptor hypofunction model of psychosis. In: Moghaddam B, Wolf ME (eds). Glutamate and Disorders of Cognition and Motivation. New York Academy of Sciences: New York. pp 119-130.
14. Farber NB, Kim SH, Dikranian K, Jiang XP, Heinkel C (2002). Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry 7: 32-43.
15. First MB, Spitzer RL, Williams JBW, Gibbon M (1995). Structured Clinical Interview for DSMIV (SCID). American Psychiatric Association: Washington, D.C.
16. Friston KJ, Holmes A, Poline JB, Price CJ, Frith CD (1996). Detecting activations in PET and fMRI: levels of inference and power. Neuroimage 4: 223-235.
17. Friston KJ, Worsley KJ, Frackowiak RSJ, Mazziotta JC, Evans AC (1994). Assessing the significance of focal activations using their spatial extent. Hum Brain Mapp 1: 210-220.
18. Giovannini MG, Mutolo D, Bianchi L, Michelassi A, Pepeu G (1994). NMDA receptor antagonists decrease GABA outflow from the septum and increase acetylcholine outflow from the hippocampus: a microdialysis study. J Neurosci 14: 1358-1365.
19. Gluck MR, Thomas RG, Davis KL, Haroutunian V (2002). Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. Am J Psychiatry 159: 1165-1173.
20. Grunze HC, Rainnie DG, Hasselmo ME, Barkai E, Hearn EF, McCarley RW et al (1996). NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 16: 2034-2043.
21. Holcomb HH, Cascella NG, Thaker GK, Medoff DR, Dannals RF, Tamminga CA (1996). Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am J Psychiatry 153: 41-49.
22. Holcomb HH, Lahti AC, Medoff DR, Weiler M, Tamminga CA (2001). Sequential regional cerebral blood flow brain scans using PET with H2(15)O demonstrate ketamine actions in CNS dynamically. Neuropsychopharmacology 25: 165-172.
23. Homayoun H, Jackson ME, Moghaddam B (2005). Activation of metabotropic glutamate 2/3 (mGlu2/3) receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol 93: 1989-2001.
24. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
25. Jentsch JD, Redmond Jr DE, Elsworth JD, Taylor JR, Youngren KD, Roth RH (1997). Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 277: 953-955.
26. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter Jr WT (1989). The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 30: 119-123.
27. Konradi C, Heckers S (2003). Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther 97: 153-179.
28. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R (2003). NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 169: 215-233.
29. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gene Psychiatry 51: 199-214.
30. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA (1995a). Ketamine activates psychosis and alters limbic blood flow in schizophrenia. NeuroReport 6: 869-872.
31. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995b). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13: 9-19.
32. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001a). Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25: 455-467.
33. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001b). Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25: 455-467.
34. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA (2003). Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117: 697-706.
35. Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A (1997). Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry 42: 664-668.
36. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D et al (1996). NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14: 301-307.
37. Moghaddam B (2003). Bringing order to the glutamate chaos in schizophrenia. Neuron 40: 881-884.
38. Moghaddam B, Adams B, Verma A, Daly D (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921-2927.
39. Moghaddam B, Adams BW (1998). Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281: 1349-1352.
40. Moghaddam B, Jackson ME (2003). Glutamatergic animal models of schizophrenia. In: Moghaddam B, Wolf ME (eds). Glutamate and Disorders of Cognition and Motivation. The New York Academy of Sciences: New York. pp 131-137.
41. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T et al (1999). Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20: 106-118.
42. Olney JW, Newcomer JW, Farber NB (1999). NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33: 523-533.
43. Overall JF, Gorham DR (1962). The brief psychiatric rating scale. Psychol Rep 10: 799-812.
44. Patel AB, De Graaf RA, Mason GF, Rothman DL, Shulman RG, Behar KL (2003). Coupling of glutamatergic neurotransmission and neuronal glucose oxidation over the entire range of cerebral cortex activity. Ann NY Acad Sci 1003: 452-453.
45. Pearlson GD (1981). Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. John Hopkins Med J 148: 25-33.
46. Rothman DL, Behar KL, Hyder F, Shulman RG (2003). In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function. Annu Rev Physiol 65: 401-427.
47. Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, Landgraf E et al (2005). Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4.0T Proton MRS study. Am J Psychiatry 162: 394-396.
48. Sharp FR, Tomitaka M, Bernaudin M, Tomitaka S (2001). Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends Neurosci 24: 330-334.
49. Shen J, Petersen KF, Behar KL, Brown P, Nixon TW, Mason GF et al (1999). Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR. Proc Natl Acad Sci USA 96: 8235-8240.
50. Shulman RG, Hyder F, Rothman DL (2002). Biophysical basis of brain activity: implications for neuroimaging. Q Rev Biophys 35: 287-325.
51. Strauss JS, Carpenter Jr WT (1974). The prediction of outcome in schizophrenia. II. Relationships between predictor and outcome variables: a report from the WHO international pilot study of schizophrenia. Arch Gene Psychiatry 31: 37-42.
52. Takahata R, Moghaddam B (2003). Activation of glutamate neurotransmission in the prefrontal cortex sustains the motoric and dopaminergic effects of phencyclidine. Neuropsychopharmacology 28: 1117-1124.
53. Tamminga CA (1998). Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 12: 21-36.
54. Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J et al (2002). Glutamate and glutamine measured with 4.0T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 159: 1944-1946.
55. Tomitaka S, Tomitaka M, Tolliver BK, Sharp FR (2000). Bilateral blockade of NMDA receptors in anterior thalamus by dizocilpine (MK-801) injures pyramidal neurons in rat retrosplenial cortex. Eur J Neurosci 12: 1420-1430.
56. Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J (1997a). Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol 7: 25-38.
57. 18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 7: 9-24.
58. 3H]phencyclidine binding in rat central nervous system. Proc Natl Acad Sci USA 76: 5372-5376.